PeptidePicker
AntimicrobialResearch

LL-37

Also known as: Cathelicidin · hCAP18

An endogenous cathelicidin antimicrobial peptide that serves as the immune system's first line of defense against bacteria, fungi, and biofilms including MRSA.

Dr. Sarah Mitchell

Reviewed by Dr. Sarah Mitchell, PharmD, BCPS

Lead Researcher · 12+ years in peptide therapeutics

Half-Life

~4 hours

Typical Dose

100–200 mcg

Administration

Subcutaneous injection

Mechanism of Action

Disrupts microbial membranes through electrostatic binding, while simultaneously modulating innate immune response and promoting epithelial tissue regeneration.

Key Research Areas

antimicrobialimmuneLymeMRSAbiofilm

Frequently Asked Questions

What is LL-37?
An endogenous cathelicidin antimicrobial peptide that serves as the immune system's first line of defense against bacteria, fungi, and biofilms including MRSA.
How does LL-37 work?
Disrupts microbial membranes through electrostatic binding, while simultaneously modulating innate immune response and promoting epithelial tissue regeneration.
What is the recommended dosage for LL-37?
The typical research dosage is 100–200 mcg, administered via Subcutaneous injection. Dosage protocols vary by study and should be determined by a qualified healthcare professional.
What is the half-life of LL-37?
The half-life of LL-37 is approximately ~4 hours. This affects dosing frequency and timing in research protocols.
Is LL-37 FDA approved?
LL-37 is currently classified as "Research" and is not FDA approved for general use. It is available for research purposes or through compounding pharmacies depending on your jurisdiction.

Research Disclaimer

The information provided about LL-37 is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.

Related Peptides in Antimicrobial